Using nanoparticles to genetically modify B cells to produce antibodies against HIV
In vivo CRISPR engineering of B cells to produce anti-HIV broadly neutralizing antibodies using novel nanoparticles
This study is exploring a new way to help people with HIV by using their own immune cells to create powerful antibodies that fight the virus, which could lead to a one-time treatment that protects them for life instead of needing ongoing medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-11301387 on NIH RePORTER |
What this research studies
This research aims to develop a novel method for treating HIV by genetically engineering a patient's own B cells to produce broadly neutralizing antibodies (bNAbs) that can combat the virus. The approach utilizes synthetic nanoparticles to deliver genetic modifications in a single step, potentially eliminating the need for complex and lengthy laboratory procedures. If successful, this method could provide a one-time treatment that offers lifelong protection against HIV, addressing the limitations of current antiretroviral therapies. Patients may benefit from a more effective and accessible treatment option that reduces the need for ongoing medication.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are seeking innovative treatment options.
Not a fit: Patients who are not infected with HIV or those who do not have access to genetic engineering therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a one-time treatment that provides lifelong immunity against HIV.
How similar studies have performed: Previous research has shown success in using genetic engineering to produce antibodies against other viruses, indicating potential for this novel approach.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Adair, Jennifer Eileen — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Adair, Jennifer Eileen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.